Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2270139 | 0.84 | HCAR2 (0.62) | TSHRMAPK10ALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL2276220 | 0.79 | L3MBTL1 (0.55) | ALDH1A1L3MBTL1RAB9ANPC1GAA | |
| SCHEMBL2269667 | 0.79 | F10 (0.53) | ALDH1A1GAAKDM4E | |
| SCHEMBL2271662 | 0.78 | KMT2A (0.57) | TSHRHSD17B10RAB9ANPC1GAA | |
| SCHEMBL2270366 | 0.78 | STK39 (0.47) | ALDH1A1L3MBTL1 | |
| SCHEMBL2269139 | 0.77 | CYP2C9 (0.47) | ALDH1A1HSD17B10RAB9ANPC1CYP2C9 | |
| SCHEMBL2275596 | 0.77 | FABP1 (0.51) | ALDH1A1RAB9ANPC1 | |
| SCHEMBL2276375 | 0.76 | GRIK1 (0.49) | TSHRRAB9ANPC1CYP1A2CYP2C9 | |
| SCHEMBL2275426 | 0.76 | GRM5 (0.46) | RAB9ANPC1 | |
| SCHEMBL14428179 | 0.76 | NPC1 (0.61) | TSHRMAPK10ALDH1A1HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | TSHR 3951/4885MAPK10 181/4885ALDH1A1 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.